Page 3 - Agepha Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Colchicine, taken with or without statins, can lower the risk of heart attack, stroke, and death in adults with atherosclerosis.

A 0.5 mg dose of colchicine, a drug commonly used for conditions such as gout, was recently approved by the FDA to prevent cardiovascular events in patients with residual inflammatory risk.It is the first anti-inflammatory agent to be approved as an atheroprotective CV treatment, according to a press release from the manufacturer, and is expected to be available later this year. News of the

A new analysis has shown a particularly large reduction in CV events and death with lipid-lowering therapy in the primary prevention population, leading to calls for more attention to be paid to this group.

The FDA has given the new low dose of colchicine a broad indication for use in atherosclerotic cardiovascular disease, but how will the drug actually be used in clinical practice?

The drug represents the first specific anti-inflammatory drug for the reduction of cardiovascular events for patients with established atherosclerotic disease or with multiple risk factors.